Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. The Complex Interrelation between Weight Loss Drugs and Substance-Related Use/Craving
3.2. Weight Loss Medication Intake and Sex Drive/Libido
3.3. Weight Loss Drugs and Behavioral Addictions (Unrelated to Food)
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Dumiaty, Y.; Underwood, B.M.; Phy-Lim, J.; Chee, M.J. Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3–36 in the suppression of food, drug-seeking, and anxiogenesis. Neuropeptides 2024, 105, 102427. [Google Scholar] [CrossRef]
- Brierley, D.I.; Holt, M.K.; Singh, A.; de Araujo, A.; McDougle, M.; Vergara, M.; Afaghani, M.H.; Lee, S.J.; Scott, K.; Maske, C.; et al. Central and peripheral GLP-1 systems independently suppress eating. Nat. Metab. 2021, 3, 258–273. [Google Scholar] [CrossRef]
- Zhao, X.; Wang, M.; Wen, Z.; Lu, Z.; Cui, L.; Fu, C.; Xue, H.; Liu, Y.; Zhang, Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol. 2021, 12, 721135. [Google Scholar] [CrossRef]
- Floresta, G.; Amata, E.; Gentile, D.; Romeo, G.; Marrazzo, A.; Pittalà, V.; Salerno, L.; Rescifina, A. Fourfold Filtered Statistical/Computational Approach for the Identification of Imidazole Compounds as HO-1 Inhibitors from Natural Products. Mar. Drugs 2019, 17, 113. [Google Scholar] [CrossRef]
- The Lancet Regional, H.-E. Semaglutide and beyond: A turning point in obesity pharmacotherapy. Lancet Reg. Health Eur. 2024, 37, 100860. [Google Scholar] [CrossRef]
- Jerlhag, E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front. Pharmacol. 2023, 14, 1063033. [Google Scholar] [CrossRef]
- Eren-Yazicioglu, C.Y.; Yigit, A.; Dogruoz, R.E.; Yapici-Eser, H. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front. Behav. Neurosci. 2020, 14, 614884. [Google Scholar] [CrossRef]
- Klausen, M.K.; Thomsen, M.; Wortwein, G.; Fink-Jensen, A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br. J. Pharmacol. 2022, 179, 625–641. [Google Scholar] [CrossRef]
- Hariyanto, T.I.; Kurniawan, A. Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment. Cancer Treat. Res. Commun. 2021, 27, 100336. [Google Scholar] [CrossRef]
- Rowlands, J.; Heng, J.; Newsholme, P.; Carlessi, R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front. Endocrinol. 2018, 9, 672. [Google Scholar] [CrossRef]
- Zhu, C.; Li, H.; Kong, X.; Wang, Y.; Sun, T.; Wang, F. Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder. Front. Pharmacol. 2022, 13, 819470. [Google Scholar] [CrossRef]
- Hernandez, N.S.; Weir, V.R.; Ragnini, K.; Merkel, R.; Zhang, Y.; Mace, K.; Rich, M.T.; Christopher Pierce, R.; Schmidt, H.D. GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA. Mol. Psychiatry 2021, 26, 4394–4408. [Google Scholar] [CrossRef]
- Rhea, E.M.; Babin, A.; Thomas, P.; Omer, M.; Weaver, R.; Hansen, K.; Banks, W.A.; Talbot, K. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases. Tissue Barriers 2023, 2292461. [Google Scholar] [CrossRef]
- Chen, X.; Chen, S.; Li, Z.; Zhu, R.; Jia, Z.; Ban, J.; Zhen, R.; Chen, X.; Pan, X.; Ren, Q.; et al. Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice. Front. Pharmacol. 2023, 14, 975830. [Google Scholar] [CrossRef]
- Kenny, P.J. Reward mechanisms in obesity: New insights and future directions. Neuron 2011, 69, 664–679. [Google Scholar] [CrossRef]
- Saper, C.B.; Chou, T.C.; Elmquist, J.K. The need to feed: Homeostatic and hedonic control of eating. Neuron 2002, 36, 199–211. [Google Scholar] [CrossRef]
- Zhou, P.; Jin, B.; Li, H.; Huang, S.Y. HPEPDOCK: A web server for blind peptide-protein docking based on a hierarchical algorithm. Nucleic Acids Res. 2018, 46, W443–W450. [Google Scholar] [CrossRef]
- Quddos, F.; Hubshman, Z.; Tegge, A.; Sane, D.; Marti, E.; Kablinger, A.S.; Gatchalian, K.M.; Kelly, A.L.; DiFeliceantonio, A.G.; Bickel, W.K. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Sci. Rep. 2023, 13, 20998. [Google Scholar] [CrossRef]
- Bornebusch, A.B.; Fink-Jensen, A.; Wörtwein, G.; Seeley, R.J.; Thomsen, M. Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs. eNeuro 2019, 6, ENEURO.0443-18.2019. [Google Scholar] [CrossRef]
- Silverii, G.A.; Marinelli, C.; Mannucci, E.; Rotella, F. Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials. Diabetes Obes. Metab. 2024, 26, 2505–2508. [Google Scholar] [CrossRef]
- Arillotta, D.; Floresta, G.; Guirguis, A.; Corkery, J.M.; Catalani, V.; Martinotti, G.; Sensi, S.L.; Schifano, F. GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sci. 2023, 13, 1503. [Google Scholar] [CrossRef]
- Chiappini, S.; Papanti Pelletier, G.D.; Vickers-Smith, R.; Corkery, J.M.; Guirguis, A.; Martinotti, G.; Schifano, F. Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: Charting a path forward. Expert Opin. Pharmacother. 2023, 24, 1915–1918. [Google Scholar] [CrossRef]
- Yaribeygi, H.; Rashidy-Pour, A.; Atkin, S.L.; Jamialahmadi, T.; Sahebkar, A. GLP-1 mimetics and cognition. Life Sci. 2021, 264, 118645. [Google Scholar] [CrossRef]
- Bendotti, G.; Montefusco, L.; Lunati, M.E.; Usuelli, V.; Pastore, I.; Lazzaroni, E.; Assi, E.; Seelam, A.J.; El Essawy, B.; Jang, J.; et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol. Res. 2022, 182, 106320. [Google Scholar] [CrossRef]
- Reich, N.; Hölscher, C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front. Neurosci. 2022, 16, 970925. [Google Scholar] [CrossRef]
- Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; et al. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 2019, 18, 41–58. [Google Scholar] [CrossRef]
- Ashburn, T.T.; Thor, K.B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004, 3, 673–683. [Google Scholar] [CrossRef]
- Alomar, M.; Tawfiq, A.M.; Hassan, N.; Palaian, S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: Current status, challenges and the future. Ther. Adv. Drug Saf. 2020, 11, 2042098620938595. [Google Scholar] [CrossRef]
- Keller, R.; Spanu, A.; Puhan, M.A.; Flahault, A.; Lovis, C.; Mütsch, M.; Beau-Lejdstrom, R. Social media and internet search data to inform drug utilization: A systematic scoping review. Front. Digit. Health 2023, 5, 1074961. [Google Scholar] [CrossRef]
- Tenderich, A.; Tenderich, B.; Barton, T.; Richards, S.E. What Are PWDs (People With Diabetes) Doing Online? A Netnographic Analysis. J. Diabetes Sci. Technol. 2019, 13, 187–197. [Google Scholar] [CrossRef]
- Ruksakulpiwat, S.; Kumar, A.; Ajibade, A. Using ChatGPT in Medical Research: Current Status and Future Directions. J. Multidiscip. Healthc. 2023, 16, 1513–1520. [Google Scholar] [CrossRef]
- Salah, M.; Al Halbusi, H.; Abdelfattah, F. May the force of text data analysis be with you: Unleashing the power of generative AI for social psychology research. Comput. Hum. Behav. Artif. Hum. 2023, 1, 100006. [Google Scholar] [CrossRef]
- Dunigan, A.I.; Roseberry, A.G. Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards. Addict. Neurosci. 2022, 2, 100011. [Google Scholar] [CrossRef]
- Davey, Z.; Schifano, F.; Corazza, O.; Deluca, P. e-Psychonauts: Conducting research in online drug forum communities. J. Ment. Health 2012, 21, 386–394. [Google Scholar] [CrossRef]
- Schoonenboom, J.; Johnson, R.B. How to Construct a Mixed Methods Research Design. Koln. Z. Soz. Sozpsychol. 2017, 69, 107–131. [Google Scholar] [CrossRef]
- Arillotta, D.; Guirguis, A.; Corkery, J.M.; Scherbaum, N.; Schifano, F. COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. Brain Sci. 2021, 11, 907. [Google Scholar] [CrossRef]
- Chen, X.; Ma, L.; Gan, K.; Pan, X.; Chen, S. Phosphorylated proteomics-based analysis of the effects of semaglutide on hippocampi of high-fat diet-induced-obese mice. Diabetol. Metab. Syndr. 2023, 15, 63. [Google Scholar] [CrossRef]
- Greenwood, M.P.; Greenwood, M.; Barez-Lopez, S.; Hawkins, J.W.; Short, K.; Tatovic, D.; Murphy, D. Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release. Mol. Metab. 2023, 70, 101692. [Google Scholar] [CrossRef]
- Hoeflich, K.P.; Ikura, M. Calmodulin in action: Diversity in target recognition and activation mechanisms. Cell 2002, 108, 739–742. [Google Scholar] [CrossRef]
- Fuochi, V.; Floresta, G.; Emma, R.; Patamia, V.; Caruso, M.; Zagni, C.; Ronchi, F.; Ronchi, C.; Drago, F.; Rescifina, A.; et al. Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43. Viruses 2023, 15, 663. [Google Scholar] [CrossRef]
- Crocetti, L.; Floresta, G.; Zagni, C.; Merugu, D.; Mazzacuva, F.; de Oliveira Silva, R.R.; Vergelli, C.; Giovannoni, M.P.; Cilibrizzi, A. Ligand Growing Experiments Suggested 4-amino and 4-ureido pyridazin-3(2H)-one as Novel Scaffold for FABP4 Inhibition. Pharmaceuticals 2022, 15, 1335. [Google Scholar] [CrossRef] [PubMed]
- Record, R.A.; Silberman, W.R.; Santiago, J.E.; Ham, T. I Sought It, I Reddit: Examining Health Information Engagement Behaviors among Reddit Users. J. Health Commun. 2018, 23, 470–476. [Google Scholar] [CrossRef]
- Hintz, E.A.; Betts, T. Reddit in communication research: Current status, future directions and best practices. Ann. Int. Commun. Assoc. 2022, 46, 116–133. [Google Scholar] [CrossRef]
- Yang, J.P.; Nhan, E.R.; Tung, E.L. COVID-19 anti-Asian racism and race-based stress: A phenomenological qualitative media analysis. Psychol. Trauma 2022, 14, 1374–1382. [Google Scholar] [CrossRef] [PubMed]
- Moreno-Ortiz, A.; García-Gámez, M. Strategies for the Analysis of Large Social Media Corpora: Sampling and Keyword Extraction Methods. Corpus Pragmat. 2023, 7, 241–265. [Google Scholar] [CrossRef]
- Faviez, C.; Talmatkadi, M.; Foulquié, P.; Mebarki, A.; Schück, S.; Burgun, A.; Chen, X. Assessment of the Early Detection of Anosmia and Ageusia Symptoms in COVID-19 on Twitter: Retrospective Study. JMIR Infodemiology 2023, 3, e41863. [Google Scholar] [CrossRef] [PubMed]
- Biswas, S.S. ChatGPT for Research and Publication: A Step-by-Step Guide. J. Pediatr. Pharmacol. Ther. 2023, 28, 576–584. [Google Scholar] [CrossRef]
- Hassani, H.; Silva, E.S. The Role of ChatGPT in Data Science: How AI-Assisted Conversational Interfaces Are Revolutionizing the Field. Big Data Cogn. Comput. 2023, 7, 62. [Google Scholar] [CrossRef]
- Ravaldi, C.; Mosconi, L.; Bonaiuti, R.; Vannacci, A. The Emotional Landscape of Pregnancy and Postpartum during the COVID-19 Pandemic in Italy: A Mixed-Method Analysis Using Artificial Intelligence. J. Clin. Med. 2023, 12, 6140. [Google Scholar] [CrossRef]
- Catalani, V.; Arillotta, D.; Corkery, J.M.; Guirguis, A.; Vento, A.; Schifano, F. Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. Front. Psychiatry 2020, 11, 632405. [Google Scholar] [CrossRef]
- Mullin, A.; Scott, M.; Vaccaro, G.; Floresta, G.; Arillotta, D.; Catalani, V.; Corkery, J.M.; Stair, J.L.; Schifano, F.; Guirguis, A. Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. Pharmacy 2024, 12, 13. [Google Scholar] [CrossRef] [PubMed]
- Kozinets, R.V.; Gambetti, R. Netnography unlimited. In Netnography Unlimited, 1st ed.; Routledge: New York, NY, USA, 2021. [Google Scholar] [CrossRef]
- Richards, J.R.; Dorand, M.F.; Royal, K.; Mnajjed, L.; Paszkowiak, M.; Simmons, W.K. Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series. J. Clin. Psychiatry 2023, 85, 50515. [Google Scholar] [CrossRef] [PubMed]
- Davies, G.; Elison, S.; Ward, J.; Laudet, A. The role of lifestyle in perpetuating substance use disorder: The Lifestyle Balance Model. Subst. Abuse Treat. Prev. Policy 2015, 10, 2. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.; Zhao, P.; Wang, W.; Guo, L.; Pan, Q. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Am. J. Geriatr. Psychiatry 2024, 32, 117–127. [Google Scholar] [CrossRef] [PubMed]
- Bergmann, N.C.; Davies, M.J.; Lingvay, I.; Knop, F.K. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes. Metab. 2023, 25, 18–35. [Google Scholar] [CrossRef] [PubMed]
- Mansur, R.B.; Lee, Y.; Subramaniapillai, M.; Brietzke, E.; McIntyre, R.S. Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology 2018, 136, 335–342. [Google Scholar] [CrossRef] [PubMed]
- Moore, P.W.; Malone, K.; VanValkenburg, D.; Rando, L.L.; Williams, B.C.; Matejowsky, H.G.; Ahmadzadeh, S.; Shekoohi, S.; Cornett, E.M.; Kaye, A.D. GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications. Adv. Ther. 2023, 40, 723–742. [Google Scholar] [CrossRef] [PubMed]
- Floresta, G.; Arillotta, D.; Catalani, V.; Papanti Pelletier, G.D.; Corkery, J.M.; Guirguis, A.; Schifano, F. Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions. Sci. Pharm. 2024, 92, 17. [Google Scholar] [CrossRef]
- Wium-Andersen, I.K.; Wium-Andersen, M.K.; Fink-Jensen, A.; Rungby, J.; Jørgensen, M.B.; Osler, M. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. Basic Clin. Pharmacol. Toxicol. 2022, 131, 372–379. [Google Scholar] [CrossRef]
- McCarty, M.F. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med. Hypotheses 2005, 64, 848–853. [Google Scholar] [CrossRef]
- Fujii, Y.; Osaki, N.; Hase, T.; Shimotoyodome, A. Ingestion of coffee polyphenols increases postprandial release of the active glucagon-like peptide-1 (GLP-1(7-36)) amide in C57BL/6J mice. J. Nutr. Sci. 2015, 4, e9. [Google Scholar] [CrossRef] [PubMed]
- Tabrizi, R.; Saneei, P.; Lankarani, K.B.; Akbari, M.; Kolahdooz, F.; Esmaillzadeh, A.; Nadi-Ravandi, S.; Mazoochi, M.; Asemi, Z. The effects of caffeine intake on weight loss: A systematic review and dos-response meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 2019, 59, 2688–2696. [Google Scholar] [CrossRef] [PubMed]
- Brunchmann, A.; Thomsen, M.; Fink-Jensen, A. The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review. Physiol. Behav. 2019, 206, 232–242. [Google Scholar] [CrossRef] [PubMed]
- Falk, S.; Petersen, J.; Svendsen, C.; Romero-Leguizamón, C.R.; Jørgensen, S.H.; Krauth, N.; Ludwig, M.Q.; Lundø, K.; Roostalu, U.; Skovbjerg, G.; et al. GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell Rep. 2023, 42, 112466. [Google Scholar] [CrossRef] [PubMed]
- Lengsfeld, S.; Burkard, T.; Meienberg, A.; Jeanloz, N.; Vukajlovic, T.; Bologna, K.; Steinmetz, M.; Bathelt, C.; Sailer, C.O.; Vogt, D.R.; et al. Effect of dulaglutide in promoting abstinence during smoking cessation: A single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine 2023, 57, 101865. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Volkow, N.D.; Berger, N.A.; Davis, P.B.; Kaelber, D.C.; Xu, R. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: A retrospective cohort study. Mol. Psychiatry 2024. online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Yammine, L.; Balderas, J.C.; Weaver, M.F.; Schmitz, J.M. Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study. J. Addict. Med. 2023, 17, 481–484. [Google Scholar] [CrossRef] [PubMed]
- Blanco-Gandia, M.C.; Montagud-Romero, S.; Rodríguez-Arias, M. Binge eating and psychostimulant addiction. World J. Psychiatry 2021, 11, 517–529. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.; Miller, R.; Groth, S.W. A literature review of dopamine in binge eating. J. Eat. Disord. 2022, 10, 11. [Google Scholar] [CrossRef]
- Pakdaman, S.; Wilcox, R.E.; Miller, J.D. Theories and treatment of drug dependency: A neurochemical perspective. Curr. Mol. Pharmacol. 2014, 7, 52–66. [Google Scholar] [CrossRef]
- Soto-Montenegro, M.L.; Vaquero, J.J.; Arango, C.; Ricaurte, G.; García-Barreno, P.; Desco, M. Effects of MDMA on blood glucose levels and brain glucose metabolism. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 916–925. [Google Scholar] [CrossRef] [PubMed]
- Rentzeperi, E.; Pegiou, S.; Koufakis, T.; Grammatiki, M.; Kotsa, K. Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. J. Pers. Med. 2022, 12, 454. [Google Scholar] [CrossRef] [PubMed]
- Vestlund, J.; Jerlhag, E. Glucagon-like peptide-1 receptors and sexual behaviors in male mice. Psychoneuroendocrinology 2020, 117, 104687. [Google Scholar] [CrossRef] [PubMed]
- Varnum, A.A.; Pozzi, E.; Deebel, N.A.; Evans, A.; Eid, N.; Sadeghi-Nejad, H.; Ramasamy, R. Impact of GLP-1 Agonists on Male Reproductive Health-A Narrative Review. Medicina 2023, 60, 50. [Google Scholar] [CrossRef] [PubMed]
- Lisco, G.; Bartolomeo, N.; De Tullio, A.; De Pergola, G.; Guastamacchia, E.; Jirillo, E.; Piazzolla, G.; Triggiani, V.; Giagulli, V.A. Long-acting glucagon-like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study. Andrology 2024, 12, 633–642. [Google Scholar] [CrossRef] [PubMed]
- Pavli, P.; Triantafyllidou, O.; Kapantais, E.; Vlahos, N.F.; Valsamakis, G. Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature. Int. J. Mol. Sci. 2024, 25, 1909. [Google Scholar] [CrossRef] [PubMed]
- Pettorruso, M.; Di Lorenzo, G.; De Risio, L.; Di Carlo, F.; d’Andrea, G.; Martinotti, G. Addiction biotypes: A paradigm shift for future treatment strategies? Mol. Psychiatry 2024. online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Butler, M.J.; Perrini, A.A.; Eckel, L.A. The Role of the Gut Microbiome, Immunity, and Neuroinflammation in the Pathophysiology of Eating Disorders. Nutrients 2021, 13, 500. [Google Scholar] [CrossRef] [PubMed]
- Breton, E.; Fotso Soh, J.; Booij, L. Immunoinflammatory processes: Overlapping mechanisms between obesity and eating disorders? Neurosci. Biobehav. Rev. 2022, 138, 104688. [Google Scholar] [CrossRef]
- Pivarunas, B.; Conner, B.T. Impulsivity and emotion dysregulation as predictors of food addiction. Eat. Behav. 2015, 19, 9–14. [Google Scholar] [CrossRef]
- Maxwell, A.L.; Gardiner, E.; Loxton, N.J. Investigating the relationship between reward sensitivity, impulsivity, and food addiction: A systematic review. Eur. Eat. Disord. Rev. 2020, 28, 368–384. [Google Scholar] [CrossRef] [PubMed]
- Dong, M.; Wen, S.; Zhou, L. The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors. Diabetes Metab. Syndr. Obes. 2022, 15, 2583–2597. [Google Scholar] [CrossRef] [PubMed]
- Imbernon, M.; Saponaro, C.; Helms, H.C.C.; Duquenne, M.; Fernandois, D.; Deligia, E.; Denis, R.G.P.; Chao, D.H.M.; Rasika, S.; Staels, B.; et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metab. 2022, 34, 1054–1063.e7. [Google Scholar] [CrossRef] [PubMed]
- Breton, J.; Galmiche, M.; Déchelotte, P. Dysbiotic Gut Bacteria in Obesity: An Overview of the Metabolic Mechanisms and Therapeutic Perspectives of Next-Generation Probiotics. Microorganisms 2022, 10, 452. [Google Scholar] [CrossRef] [PubMed]
- Day, A.W.; Kumamoto, C.A. Gut Microbiome Dysbiosis in Alcoholism: Consequences for Health and Recovery. Front. Cell Infect. Microbiol. 2022, 12, 840164. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Y.; Gan, L.; Ren, L.; Lin, Y.; Ma, C.; Lin, X. Factors influencing the blood-brain barrier permeability. Brain Res. 2022, 1788, 147937. [Google Scholar] [CrossRef] [PubMed]
- Rubino, D.; Abrahamsson, N.; Davies, M.; Hesse, D.; Greenway, F.L.; Jensen, C.; Lingvay, I.; Mosenzon, O.; Rosenstock, J.; Rubio, M.A.; et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021, 325, 1414–1425. [Google Scholar] [CrossRef]
- Dong, Y.; Carty, J.; Goldstein, N.; He, Z.; Hwang, E.; Chau, D.; Wallace, B.; Kabahizi, A.; Lieu, L.; Peng, Y.; et al. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Mol. Metab. 2021, 54, 101352. [Google Scholar] [CrossRef]
- Diz-Chaves, Y.; Herrera-Pérez, S.; González-Matías, L.C.; Lamas, J.A.; Mallo, F. Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress. Nutrients 2020, 12, 3304. [Google Scholar] [CrossRef] [PubMed]
- Campos, A.; Port, J.D.; Acosta, A. Integrative Hedonic and Homeostatic Food Intake Regulation by the Central Nervous System: Insights from Neuroimaging. Brain Sci. 2022, 12, 431. [Google Scholar] [CrossRef]
- Muller, D.R.P.; Stenvers, D.J.; Malekzadeh, A.; Holleman, F.; Painter, R.C.; Siegelaar, S.E. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: A systematic review of the evidence. Front. Endocrinol. 2023, 14, 1215356. [Google Scholar] [CrossRef] [PubMed]
- Harris, E. First Large Study of GLP-1 Receptor Agonists During Pregnancy. JAMA 2024, 331, 280. [Google Scholar] [CrossRef] [PubMed]
- Bartel, S.; McElroy, S.L.; Levangie, D.; Keshen, A. Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. Int. J. Eat. Disord. 2024, 57, 286–293. [Google Scholar] [CrossRef] [PubMed]
- Peng, W.; Zhou, R.; Sun, Z.F.; Long, J.W.; Gong, Y.Q. Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases. Aging Dis. 2022, 13, 468–490. [Google Scholar] [CrossRef] [PubMed]
- Arnold, C. After obesity drugs’ success, companies rush to preserve skeletal muscle. Nat. Biotechnol. 2024, 42, 351–353. [Google Scholar] [CrossRef] [PubMed]
- Hayashi, D.; Edwards, C.; Emond, J.A.; Gilbert-Diamond, D.; Butt, M.; Rigby, A.; Masterson, T.D. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients 2023, 15, 4809. [Google Scholar] [CrossRef] [PubMed]
- Poisson, C.L.; Engel, L.; Saunders, B.T. Dopamine Circuit Mechanisms of Addiction-Like Behaviors. Front. Neural Circuits 2021, 15, 752420. [Google Scholar] [CrossRef]
- Xue, J.; Qian, D.; Zhang, B.; Yang, J.; Li, W.; Bao, Y.; Qiu, S.; Fu, Y.; Wang, S.; Yuan, T.F.; et al. Midbrain dopamine neurons arbiter OCD-like behavior. Proc. Natl. Acad. Sci. USA 2022, 119, e2207545119. [Google Scholar] [CrossRef]
- Castillo-Toledo, C.; Fraile-Martínez, O.; Donat-Vargas, C.; Lara-Abelenda, F.J.; Ortega, M.A.; Garcia-Montero, C.; Mora, F.; Alvarez-Mon, M.; Quintero, J.; Alvarez-Mon, M.A. Insights from the Twittersphere: A cross-sectional study of public perceptions, usage patterns, and geographical differences of tweets discussing cocaine. Front. Psychiatry 2024, 15, 1282026. [Google Scholar] [CrossRef]
- Guirguis, A.; Chiappini, S.; Papanti, P.G.; Vickers-Smith, R.; Harris, D.; Corkery, J.M.; Arillotta, D.; Floresta, G.; Martinotti, G.; Schifano, F. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. Eur. Neuropsychopharmacol. 2024, 82, 82–91. [Google Scholar] [CrossRef]
Substance addictions/craving for commonly used drugs (legal and not legal) | ||||||
Alcohol, alcoholism | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
alcohol | 123 | 60 | 31 | 2 | 169 | 385 |
alcoholism | 0 | 0 | 0 | 0 | 17 | 17 |
alcoholic | 7 | 3 | 0 | 0 | 25 | 35 |
130 (29.75%) | 63 (14.42%) | 31 (7.09%) | 2 (0.46%) | 211 (48.28%) | 437 | |
Other drinking habits: coffee drinks | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
caffeine | 10 | 3 | 4 | 0 | 16 | 33 |
coffee | 38 | 26 | 72 | 0 | 47 | 183 |
48 (22.22%) | 29 (13.43%) | 76 (35.19%) | 0 (0.00%) | 63 (29.17%) | 216 | |
Tobacco | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
nicotine | 1 | 0 | 0 | 0 | 0 | 1 |
cigarette | 2 | 1 | 0 | 0 | 9 | 12 |
3 (23.08%) | 1 (7.69%) | 0 (0.00%) | 0 (0.00%) | 9 (69.23%) | 13 | |
Cannabis-derived products (inhaled and edibles) | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
cannabis | 2 | 1 | 2 | 0 | 4 | 9 |
weed | 0 | 1 | 1 | 0 | 15 | 17 |
edibles | 9 | 9 | 9 | 9 | 9 | 45 |
munchies | 1 | 2 | 6 | 0 | 10 | 19 |
12 (13.33%) | 13 (14.44%) | 18 (20.00%) | 9 (10.00%) | 38 (42.22%) | 90 | |
Vaping and smoking/inhaling habits (excluding psychostimulants such as cocaine and amphetamines): tobacco and cannabis-derived products | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
vaping | 1 | 2 | 1 | 0 | 2 | 6 |
smoke | 3 | 4 | 11 | 0 | 22 | 40 |
smoking | 18 | 1 | 6 | 1 | 44 | 70 |
22 (18.97%) | 7 (6.03%) | 18 (15.52%) | 1 (0.86%) | 68 (58.62%) | 116 | |
Sex drive and libido | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
sex | 0 | 1 | 0 | 5 | 27 | 33 |
libido | 0 | 1 | 0 | 1 | 2 | 4 |
0 (0.00%) | 2 (5.41%) | 0 (0.00%) | 6 (16.22%) | 29 (78.38%) | 37 | |
Behavioral addictions (excluding food) | ||||||
Shopping | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
compulsive shopping | 2 | 0 | 0 | 0 | 1 | 3 |
shopping | 19 | 6 | 14 | 2 | 45 | 86 |
21 (23.60%) | 6 (6.74%) | 14 (15.73%) | 2 (2.25%) | 46 (51.69%) | 89 |
Psychostimulants: cocaine and amphetamines | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
cocaine | 0 | 0 | 0 | 0 | 10 | 10 |
amphetamine | 0 | 0 | 0 | 0 | 8 | 8 |
0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 18 (100%) | 18 | |
Other substances (e.g., opioids such as fentanyl, heroin; painkillers; benzodiazepines; ketamine; empathogens such as MDMA; psychedelics such as magic mushrooms and psilocybin): none/not relevant | ||||||
stopped | reduced | same | increased | other topics * | total | |
/ | 0 | 0 | 0 | 0 | 0 | 0 |
0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 | |
Gaming and internet addiction | ||||||
Keywords | stopped | reduced | same | increased | other topics * | total |
gaming | 0 | 0 | 0 | 0 | 4 | 4 |
internet addiction | 0 | 0 | 0 | 0 | 0 | 0 |
0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 4 (100%) | 4 | |
Other behavioral addictions (e.g., gambling): none/not relevant | ||||||
stopped | reduced | same | increased | other topics * | total | |
/ | 0 | 0 | 0 | 0 | 0 | 0 |
0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 |
Themes |
---|
|
|
|
|
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Arillotta, D.; Floresta, G.; Papanti Pelletier, G.D.; Guirguis, A.; Corkery, J.M.; Martinotti, G.; Schifano, F. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sci. 2024, 14, 617. https://doi.org/10.3390/brainsci14060617
Arillotta D, Floresta G, Papanti Pelletier GD, Guirguis A, Corkery JM, Martinotti G, Schifano F. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sciences. 2024; 14(6):617. https://doi.org/10.3390/brainsci14060617
Chicago/Turabian StyleArillotta, Davide, Giuseppe Floresta, G. Duccio Papanti Pelletier, Amira Guirguis, John Martin Corkery, Giovanni Martinotti, and Fabrizio Schifano. 2024. "Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach" Brain Sciences 14, no. 6: 617. https://doi.org/10.3390/brainsci14060617